Jim Carmichael is currently working at Bristol Myers Squibb, in Integrative Sciences and is based in the UK.  He was an academic Oncologist who joined industry in 2002 with AstraZeneca and subsequently joined Celgene as Chief Scientific Officer for the Celgene Institute Translational Research Europe (CITRE) in July 2011.

Early Medical Oncology training was at the University of Edinburgh, followed by a Fellowship at the National Cancer Institute. He held senior positions, initially at the University of Oxford, then as the Head and Chair of the Cancer Research UK Department of Clinical Oncology at the University of Nottingham.

He joined the pharmaceutical industry in 2002 joining AstraZeneca to lead the Experimental Medicine group, based at Alderley Park, Cheshire.  In 2006 he moved to take up the role of Chief Medical Officer for KuDOS Pharmaceuticals, where the focus was the development of cancer drugs targeted at DNA repair and was responsible for the early clinical development of Olaparib.  In 2011, he moved to Celgene to take up the position of Chief Scientific Officer at CITRE, where he built the research team from scratch and was Site Head from 2011-2019. In 2015-2017 he had a secondment to San Diego where he led the Protein Homeostasis Thematic Centre of Excellence as part of Celgene R&D.  Following the Celgene acquisition in December 2019 he joined BMS as VP for Integrative Sciences, which bridges R&D with key collaborators in Industry and Academia, and is currently based in Europe.